The thresholds reported in preclinical literature vary: PCB-157 : 10 g/kg to 1 mg/kg subcutaneously or intraperitoneally depending on the model
IF YOU HAVE QUESTIONS OR REQUIRE MORE INFORMATION ABOUT A PRODUCT, YOU SHOULD CONTACT THE MANUFACTURER DIRECTLY
This line of work later led to a separate, FDA-reviewed compound, bremelanotide, which you can read about on our PT-141 page
As a general rule, the more tissue that can be obtained, the better the pathologist's interpretation of the tissue abnormalities will be
GLP-1 medications can cause fatigue through several mechanisms including reduced caloric intake due to appetite suppression, gastrointestinal side effects leading to dehydration and electrolyte imbalances, and metabolic adjustment to improved blood glucose control
The answers to these questions will be discussed here